Fibrinogen Concentrate (Riastap)

How it works

It replaces fibrinogen (factor I), the precursor that thrombin converts to fibrin to form a stable blood clot.

Prescribing in practice

• Thromboembolic events can occur, so it should be used only for appropriate bleeding or deficiency and with caution in patients at thrombotic risk.
• Dosing should be guided by fibrinogen levels or validated point-of-care testing where possible.
• As a plasma-derived product, batch records should be kept and standard transmissible-agent precautions apply.

Monitoring

Monitor plasma fibrinogen levels, clinical bleeding response and for signs of thromboembolism during treatment.

Counselling the patient

• Report symptoms of clots such as leg pain or swelling, chest pain or breathlessness promptly.
• Inform the team of any history of thrombosis before administration.
• This product is made from human plasma and is given under specialist supervision.

Evidence & guidelines

Its use in congenital and acquired fibrinogen deficiency is supported by haematology guidance on bleeding management and product labelling.